Compare TNET & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNET | ABCL |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | Canada |
| Employees | 2700 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.5B |
| IPO Year | 2000 | 2020 |
| Metric | TNET | ABCL |
|---|---|---|
| Price | $69.25 | $11.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $65.80 | $8.40 |
| AVG Volume (30 Days) | 299.0K | ★ 5.2M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 3.05 | N/A |
| Revenue | ★ $5,010,000,000.00 | $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.30 | $21.85 |
| P/E Ratio | $21.64 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $33.67 | $2.75 |
| 52 Week High | $73.08 | $12.58 |
| Indicator | TNET | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 54.36 | 56.96 |
| Support Level | $64.80 | $10.44 |
| Resistance Level | $72.19 | $12.58 |
| Average True Range (ATR) | 2.28 | 0.65 |
| MACD | -0.57 | -0.27 |
| Stochastic Oscillator | 57.92 | 37.61 |
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.